Piramal Pharma Limited (PPL) is a global pharmaceutical company headquartered in India that operates across the drug lifecycle, from drug discovery and process development through commercial manufacturing. It runs three business segments. Piramal Pharma Solutions (PPS) is an integrated contract development and manufacturing organization (CDMO) covering clinical trial supplies and the commercial manufacture of APIs and finished dosage forms, with specialised capabilities in highly potent APIs, antibody drug conjugates, peptides and hormonal formulations. Piramal Critical Care (PCC) supplies inhaled anesthetics and hospital generics. Piramal Consumer Healthcare sells over-the-counter products in India. PPL also holds a majority stake in Yapan Bio, a CDMO specialising in vaccines and biologics.
The company maintains 17 development and manufacturing facilities and distributes products in more than 100 countries. Technical domains span pharmaceutical development, API and finished dosage form manufacturing, highly potent compounds, peptides, hormonal formulations, inhaled anesthetics, vaccines and biologics, drug discovery, process development, clinical trial supplies and regulatory compliance.
Work at PPL takes place in a highly regulated operating environment. The company states an emphasis on the highest standards of quality, safety and regulatory compliance, and describes a science-led approach that combines scientific expertise with advanced technologies. Its stated culture is guided by the principle of "Doing Well & Doing Good", with a focus on patient-centric solutions.
